Mereo BioPharma Files 2024 10-K
Ticker: MREO · Form: 10-K · Filed: Mar 26, 2025 · CIK: 1719714
| Field | Detail |
|---|---|
| Company | Mereo Biopharma Group PLC (MREO) |
| Form Type | 10-K |
| Filed Date | Mar 26, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-K, biopharma, annual-report, drug-development
TL;DR
Mereo BioPharma's 2024 10-K is in. Check out their pipeline and financials.
AI Summary
Mereo BioPharma Group plc filed its 2024 10-K on March 26, 2025, detailing its fiscal year ending December 31, 2024. The company, operating in pharmaceutical preparations, is focused on its pipeline including Etigilimab (MPH-313). The filing covers various financial aspects, including share-based compensation and equity incentive plans like the Mereo Two Thousand and Nineteen Equity Incentive Plan.
Why It Matters
This filing provides investors with a comprehensive overview of Mereo BioPharma's financial health and operational status for the fiscal year 2024, including details on their drug development programs.
Risk Assessment
Risk Level: medium — As a biopharmaceutical company, Mereo BioPharma faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024-12-31 — Fiscal Year End (Reporting period for the 10-K)
- 2025-03-26 — Filing Date (Date the 10-K was submitted to the SEC)
Key Players & Entities
- Mereo BioPharma Group plc (company) — Filer of the 10-K
- 2024-12-31 (date) — Fiscal year end
- 2025-03-26 (date) — Filing date
- Etigilimab (MPH-313) (drug_candidate) — Key product in development
- Mereo Two Thousand and Nineteen Equity Incentive Plan (plan) — Equity incentive plan
FAQ
What is the primary focus of Mereo BioPharma's business operations as detailed in the 10-K?
Mereo BioPharma Group plc is focused on the development and commercialization of therapeutics, with specific mention of Etigilimab (MPH-313) as a key product candidate.
What is the reporting period covered by this 10-K filing?
This 10-K filing covers the fiscal year ending December 31, 2024.
When was this 10-K filed with the SEC?
This 10-K was filed on March 26, 2025.
What are some of the equity incentive plans mentioned in the filing?
The filing mentions the Mereo Two Thousand and Nineteen Equity Incentive Plan and the Two Thousand Ans Nineteen Non-Executive Director Equity Incentive Plan.
What is the SIC code for Mereo BioPharma Group plc?
The Standard Industrial Classification (SIC) code for Mereo BioPharma Group plc is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 10-K (Form 10-K) was filed with the SEC on March 26, 2025 regarding Mereo BioPharma Group plc (MREO).